Pasithea Therapeutics Corp.
NASDAQPasithea Therapeutics Corp. heads into mid-May with its most notable story in the lending market: short sellers have been quietly backing away, and the cost to borrow is following them down. Short interest has fallen sharply. The estimated short position dropped 34% over the past week to roughly 243,000 shares — back near where it stood in mid-April, after peaking above 380,000…
Snapshot as of 16 May 2026
Pasithea Therapeutics Corp. heads into mid-May with its most notable story in the lending market: short sellers have been quietly backing away, and the cost to borrow is following them down. Short interest has fallen…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KTTA — free to start on ORTEX.
Sign up for free →Open KTTA on ORTEX